News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Valeritas To Release Second Quarter 2017 Financial Results And Host Conference Call On Friday, August 11, 2017

7/28/2017 10:59:00 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will release its second quarter 2017 financial results on Friday, August 11, 2017, before market open.

Valeritas will hold a conference call on Friday, August 11, 2017, at 11:00 a.m. EDT to discuss the results. The dial-in numbers are (833) 235-7647 for domestic callers and (647) 689-4168 for international callers. The conference ID number is 56805537. A live webcast of the conference call will be available on the investor relations page of the Valeritas corporate website at

If you are unable to participate during the live webcast, a replay will remain available until Valeritas reports its third quarter 2017 financial results on the investor relations page of the Valeritas corporate website at In addition, a telephonic replay of the call will be available through August 12, 2017. The replay dial-in numbers are (800) 585-8367 for domestic callers and (416) 621-4642 for international callers. Please use the replay pin number 56805537.

About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit

Investor Contacts: Robert Flamm, Ph.D. / Brian Johnston The Ruth Group 646-536-7017 / 7028 Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 Media Contact: Kirsten Thomas / Cari Randall The Ruth Group 508-280-6592 / 646-536-7002

Read at

comments powered by Disqus